請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/21904
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊文欽 | |
dc.contributor.author | Ming-Guang Huang | en |
dc.contributor.author | 黃明光 | zh_TW |
dc.date.accessioned | 2021-06-08T03:52:22Z | - |
dc.date.copyright | 2018-08-21 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-08-18 | |
dc.identifier.citation | 1. Zimmet, P., K.G. Alberti, and J. Shaw, Global and societal implications of the diabetes epidemic. Nature, 2001. 414(6865): p. 782-7.
2. Forbes, J.M. and M.E. Cooper, Mechanisms of diabetic complications. Physiol Rev, 2013. 93(1): p. 137-88. 3. Jiang, Y.D., et al., Incidence and prevalence rates of diabetes mellitus in Taiwan: analysis of the 2000-2009 Nationwide Health Insurance database. J Formos Med Assoc, 2012. 111(11): p. 599-604. 4. Saini, V., Molecular mechanisms of insulin resistance in type 2 diabetes mellitus. World J Diabetes, 2010. 1(3): p. 68-75. 5. Krssak, M., et al., Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia, 1999. 42(1): p. 113-6. 6. Zick, Y., Insulin resistance: a phosphorylation-based uncoupling of insulin signaling. Trends Cell Biol, 2001. 11(11): p. 437-41. 7. Fu, Z., E.R. Gilbert, and D. Liu, Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. Curr Diabetes Rev, 2013. 9(1): p. 25-53. 8. Campbell, J.E. and D.J. Drucker, Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab, 2013. 17(6): p. 819-37. 9. Kulkarni, R.N., The islet beta-cell. Int J Biochem Cell Biol, 2004. 36(3): p. 365-71. 10. Wilcox, G., Insulin and insulin resistance. Clin Biochem Rev, 2005. 26(2): p. 19-39. 11. Chen, L., et al., Regulation of beta-cell glucose transporter gene expression. Proc Natl Acad Sci U S A, 1990. 87(11): p. 4088-92. 12. Ohara-Imaizumi, M. and S. Nagamatsu, Insulin exocytotic mechanism by imaging technique. J Biochem, 2006. 140(1): p. 1-5. 13. Leto, D. and A.R. Saltiel, Regulation of glucose transport by insulin: traffic control of GLUT4. Nat Rev Mol Cell Biol, 2012. 13(6): p. 383-96. 14. Kang, S., L.T. Tsai, and E.D. Rosen, Nuclear Mechanisms of Insulin Resistance. Trends Cell Biol, 2016. 26(5): p. 341-351. 15. Hotamisligil, G.S., Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell, 2010. 140(6): p. 900-17. 16. Houstis, N., E.D. Rosen, and E.S. Lander, Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature, 2006. 440(7086): p. 944-8. 17. James, A.M., et al., Mitochondrial oxidative stress and the metabolic syndrome. Trends Endocrinol Metab, 2012. 23(9): p. 429-34. 18. Olefsky, J.M. and C.K. Glass, Macrophages, inflammation, and insulin resistance. Annu Rev Physiol, 2010. 72: p. 219-46. 19. Yamauchi, T., et al., The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med, 2001. 7(8): p. 941-6. 20. Flier, J.S., Obesity wars: molecular progress confronts an expanding epidemic. Cell, 2004. 116(2): p. 337-50. 21. Kondo, H., et al., Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes, 2002. 51(7): p. 2325-8. 22. Considine, R.V., et al., Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med, 1996. 334(5): p. 292-5. 23. Kadowaki, T. and T. Yamauchi, Adiponectin and adiponectin receptors. Endocr Rev, 2005. 26(3): p. 439-51. 24. Yadav, A., M.A. Kataria, and V. Saini, Role of leptin and adiponectin in insulin resistance. Clin Chim Acta, 2013. 417: p. 80-4. 25. Chung, W.K., et al., Genomic structure of the human OB receptor and identification of two novel intronic microsatellites. Genome Res, 1996. 6(12): p. 1192-9. 26. Zhang, Y., et al., Positional cloning of the mouse obese gene and its human homologue. Nature, 1994. 372(6505): p. 425-32. 27. Ashcroft, F.M. and P. Rorsman, Diabetes mellitus and the beta cell: the last ten years. Cell, 2012. 148(6): p. 1160-71. 28. Steil, G.M., et al., Adaptation of beta-cell mass to substrate oversupply: enhanced function with normal gene expression. Am J Physiol Endocrinol Metab, 2001. 280(5): p. E788-96. 29. Jetton, T.L., et al., Mechanisms of compensatory beta-cell growth in insulin-resistant rats: roles of Akt kinase. Diabetes, 2005. 54(8): p. 2294-304. 30. Liu, Y.Q., T.L. Jetton, and J.L. Leahy, beta-Cell adaptation to insulin resistance. Increased pyruvate carboxylase and malate-pyruvate shuttle activity in islets of nondiabetic Zucker fatty rats. J Biol Chem, 2002. 277(42): p. 39163-8. 31. Chen, C., et al., Mechanism of compensatory hyperinsulinemia in normoglycemic insulin-resistant spontaneously hypertensive rats. Augmented enzymatic activity of glucokinase in beta-cells. J Clin Invest, 1994. 94(1): p. 399-404. 32. Do, O.H., et al., Changes in beta cell function occur in prediabetes and early disease in the Lepr (db) mouse model of diabetes. Diabetologia, 2016. 59(6): p. 1222-30. 33. Srinivasan, S., et al., Glucose promotes pancreatic islet beta-cell survival through a PI 3-kinase/Akt-signaling pathway. Am J Physiol Endocrinol Metab, 2002. 283(4): p. E784-93. 34. van Citters, G.W., et al., Elevated glucagon-like peptide-1-(7-36)-amide, but not glucose, associated with hyperinsulinemic compensation for fat feeding. J Clin Endocrinol Metab, 2002. 87(11): p. 5191-8. 35. Poitout, V., et al., Glucolipotoxicity of the pancreatic beta cell. Biochim Biophys Acta, 2010. 1801(3): p. 289-98. 36. Brownlee, M., A radical explanation for glucose-induced beta cell dysfunction. J Clin Invest, 2003. 112(12): p. 1788-90. 37. Kovacic, P., et al., Mechanism of mitochondrial uncouplers, inhibitors, and toxins: focus on electron transfer, free radicals, and structure-activity relationships. Curr Med Chem, 2005. 12(22): p. 2601-23. 38. Pastor, N., et al., A detailed interpretation of OH radical footprints in a TBP-DNA complex reveals the role of dynamics in the mechanism of sequence-specific binding. J Mol Biol, 2000. 304(1): p. 55-68. 39. Valko, M., et al., Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem, 2004. 266(1-2): p. 37-56. 40. Valko, M., et al., Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol, 2007. 39(1): p. 44-84. 41. Jones, S.A., et al., Expression of phagocyte NADPH oxidase components in human endothelial cells. Am J Physiol, 1996. 271(4 Pt 2): p. H1626-34. 42. Albelda, S.M., C.W. Smith, and P.A. Ward, Adhesion molecules and inflammatory injury. FASEB J, 1994. 8(8): p. 504-12. 43. Hengartner, M.O., The biochemistry of apoptosis. Nature, 2000. 407(6805): p. 770-6. 44. Carr, A.C., M.R. McCall, and B. Frei, Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol, 2000. 20(7): p. 1716-23. 45. Cameron, E. and L. Pauling, Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A, 1976. 73(10): p. 3685-9. 46. Stadtman, E.R., Role of oxidant species in aging. Curr Med Chem, 2004. 11(9): p. 1105-12. 47. Eleazu, C.O., et al., Review of the mechanism of cell death resulting from streptozotocin challenge in experimental animals, its practical use and potential risk to humans. J Diabetes Metab Disord, 2013. 12(1): p. 60. 48. Goyal, S.N., et al., Challenges and issues with streptozotocin-induced diabetes - A clinically relevant animal model to understand the diabetes pathogenesis and evaluate therapeutics. Chem Biol Interact, 2016. 244: p. 49-63. 49. Ventura-Sobrevilla, J., et al., Effect of varying dose and administration of streptozotocin on blood sugar in male CD1 mice. Proc West Pharmacol Soc, 2011. 54: p. 5-9. 50. McCord, J.M. and I. Fridovich, Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem, 1969. 244(22): p. 6049-55. 51. Pastore, A., et al., Analysis of glutathione: implication in redox and detoxification. Clin Chim Acta, 2003. 333(1): p. 19-39. 52. German, M.S., Glucose sensing in pancreatic islet beta cells: the key role of glucokinase and the glycolytic intermediates. Proc Natl Acad Sci U S A, 1993. 90(5): p. 1781-5. 53. Bindokas, V.P., et al., Visualizing superoxide production in normal and diabetic rat islets of Langerhans. J Biol Chem, 2003. 278(11): p. 9796-801. 54. Du, T.T., et al., Comparison of the performance of HbA1c and fasting plasma glucose in identifying dysglycaemic status in Chinese high-risk subjects. Clin Exp Pharmacol Physiol, 2013. 40(2): p. 63-8. 55. Riddle, M.C., Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation, 2010. 122(8): p. 844-6. 56. Shyr, Y.M., Pancreas transplantation. J Chin Med Assoc, 2009. 72(1): p. 4-9. 57. Juang, J.H., Islet transplantation: an update. Chang Gung Med J, 2004. 27(1): p. 1-15. 58. Swinnen, S.G., J.B. Hoekstra, and J.H. DeVries, Insulin therapy for type 2 diabetes. Diabetes Care, 2009. 32 Suppl 2: p. S253-9. 59. Inzucchi, S.E., Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA, 2002. 287(3): p. 360-72. 60. Szoke, E. and J.E. Gerich, Role of impaired insulin secretion and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Compr Ther, 2005. 31(2): p. 106-12. 61. Holman, R.R., et al., 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008. 359(15): p. 1577-89. 62. Zhou, G., et al., Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 2001. 108(8): p. 1167-74. 63. Musi, N., et al., Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes, 2002. 51(7): p. 2074-81. 64. Yki-Jarvinen, H., Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev, 2002. 18 Suppl 3: p. S77-81. 65. Yki-Jarvinen, H., Thiazolidinediones. N Engl J Med, 2004. 351(11): p. 1106-18. 66. Shaya, F.T., et al., Medicaid managed care: disparities in the use of thiazolidinediones compared with metformin. J Natl Med Assoc, 2005. 97(4): p. 493-7. 67. Home, P.D., et al., Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet, 2009. 373(9681): p. 2125-35. 68. Yee, H.S. and N.T. Fong, A review of the safety and efficacy of acarbose in diabetes mellitus. Pharmacotherapy, 1996. 16(5): p. 792-805. 69. Ding, S.Y., et al., Glucagon-like peptide 1 stimulates post-translational activation of glucokinase in pancreatic beta cells. J Biol Chem, 2011. 286(19): p. 16768-74. 70. Nicolaus, M., et al., Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying. J Clin Endocrinol Metab, 2011. 96(1): p. 229-36. 71. Weber, A.E., Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem, 2004. 47(17): p. 4135-41. 72. Del Prato, S. and P. Marchetti, Beta- and alpha-cell dysfunction in type 2 diabetes. Horm Metab Res, 2004. 36(11-12): p. 775-81. 73. Katsuno, K., et al., Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther, 2007. 320(1): p. 323-30. 74. Russo, G.T., et al., Factors associated with beta-cell dysfunction in type 2 diabetes: the BETADECLINE study. PLoS One, 2014. 9(10): p. e109702. 75. Leahy, J.L., et al., Targeting beta-cell function early in the course of therapy for type 2 diabetes mellitus. J Clin Endocrinol Metab, 2010. 95(9): p. 4206-16. 76. Choi, H.M., et al., An age-dependent alteration of the respiratory exchange ratio in the db/db mouse. Lab Anim Res, 2015. 31(1): p. 1-6. 77. Brandi, L.S., R. Bertolini, and M. Calafa, Indirect calorimetry in critically ill patients: clinical applications and practical advice. Nutrition, 1997. 13(4): p.349-58. 78. Battezzati, A. and R. Vigano, Indirect calorimetry and nutritional problems in clinical practice. Acta Diabetol, 2001. 38(1): p. 1-5. 79. Schwenk, A., P.T. Merilainen, and D.C. Macallan, Indirect calorimetry in patients with active respiratory infection-- prevention of cross-infection. Clin Nutr, 2002. 21(5): p. 385-8. 80. G, L.K., Measurements in physical therapy by Jules M. Rothstein Clinics in Physical Therapy Vol. 7. Churchill Livingstone, 1985. pound27.50. Clin Biomech (Bristol, Avon), 1987. 2(1): p. 61. 81. Jousilahti, P., et al., Body weight, cardiovascular risk factors, and coronary mortality. 15-year follow-up of middle-aged men and women in eastern Finland. Circulation, 1996. 93(7): p. 1372-9. 82. Shaper, A.G., S.G. Wannamethee, and M. Walker, Body weight: implications for the prevention of coronary heart disease, stroke, and diabetes mellitus in a cohort study of middle aged men. BMJ, 1997. 314(7090): p. 1311-7. 83. Copeland, K.C., et al., Management of newly diagnosed type 2 Diabetes Mellitus (T2DM) in children and adolescents. Pediatrics, 2013. 131(2): p. 364-82. 84. McGavock, J., E. Sellers, and H. Dean, Physical activity for the prevention and management of youth-onset type 2 diabetes mellitus: focus on cardiovascular complications. Diab Vasc Dis Res, 2007. 4(4): p. 305-10. 85. Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study. Int J Obes (Lond), 2010. 34(2): p. 217-26. 86. Colman, R.J., et al., Caloric restriction delays disease onset and mortality in rhesus monkeys. Science, 2009. 325(5937): p. 201-4. 87. Koubova, J. and L. Guarente, How does calorie restriction work? Genes Dev, 2003. 17(3): p. 313-21. 88. Hebert, A.S., et al., Calorie restriction and SIRT3 trigger global reprogramming of the mitochondrial protein acetylome. Mol Cell, 2013. 49(1): p. 186-99. 89. Kim, K.E., et al., Caloric restriction of db/db mice reverts hepatic steatosis and body weight with divergent hepatic metabolism. Sci Rep, 2016. 6: p. 30111. 90. Kajita, K., et al., Effect of fasting on PPARgamma and AMPK activity in adipocytes. Diabetes Res Clin Pract, 2008. 81(2): p. 144-9. 91. Corton, J.M., J.G. Gillespie, and D.G. Hardie, Role of the AMP-activated protein kinase in the cellular stress response. Curr Biol, 1994. 4(4): p. 315-24. 92. Winzell, M.S. and B. Ahren, The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes, 2004. 53 Suppl 3: p. S215-9. 93. Surwit, R.S., et al., Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism, 1995. 44(5): p. 645-51. 94. DeFronzo, R.A. and D. Tripathy, Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care, 2009. 32 Suppl 2: p. S157-63. 95. DeFronzo, R.A., et al., Synergistic interaction between exercise and insulin on peripheral glucose uptake. J Clin Invest, 1981. 68(6): p. 1468-74. 96. Lima, A.F., et al., Acute exercise reduces insulin resistance-induced TRB3 expression and amelioration of the hepatic production of glucose in the liver of diabetic mice. J Cell Physiol, 2009. 221(1): p. 92-7. 97. Blair, S.N., et al., Changes in physical fitness and all-cause mortality. A prospective study of healthy and unhealthy men. JAMA, 1995. 273(14): p. 1093-8. 98. Ross, R., et al., Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med, 2000. 133(2): p. 92-103. 99. Church, T.S., et al., Cardiorespiratory fitness and body mass index as predictors of cardiovascular disease mortality among men with diabetes. Arch Intern Med, 2005. 165(18): p. 2114-20. 100. Ryder, J.W., A.V. Chibalin, and J.R. Zierath, Intracellular mechanisms underlying increases in glucose uptake in response to insulin or exercise in skeletal muscle. Acta Physiol Scand, 2001. 171(3): p. 249-57. 101. Zisman, A., et al., Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat Med, 2000. 6(8): p. 924-8. 102. Liu, X., et al., AMPK binds to Sestrins and mediates the effect of exercise to increase insulin-sensitivity through autophagy. Metabolism, 2015. 64(6): p. 658-65. 103. Cheng, C.W., et al., Fasting-Mimicking Diet Promotes Ngn3-Driven beta-Cell Regeneration to Reverse Diabetes. Cell, 2017. 168(5): p. 775-788 e12. 104. Mihaylova, M.M. and R.J. Shaw, The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol, 2011. 13(9): p. 1016-23. 105. Kahn, B.B., et al., AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab, 2005. 1(1): p. 15-25. 106. Hardie, D.G., D. Carling, and S.J. Gamblin, AMP-activated protein kinase: also regulated by ADP? Trends Biochem Sci, 2011. 36(9): p. 470-7. 107. Zang, M., et al., Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes, 2006. 55(8): p. 2180-91. 108. Sakamoto, K. and G.D. Holman, Emerging role for AS160/TBC1D4 and TBC1D1 in the regulation of GLUT4 traffic. Am J Physiol Endocrinol Metab, 2008. 295(1): p. E29-37. 109. Carling, D., V.A. Zammit, and D.G. Hardie, A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett, 1987. 223(2): p. 217-22. 110. Hardie, D.G., AMP-activated protein kinase: the guardian of cardiac energy status. J Clin Invest, 2004. 114(4): p. 465-8. 111. Galligan, J.J. and D.R. Petersen, The human protein disulfide isomerase gene family. Hum Genomics, 2012. 6: p. 6. 112. Turano, C., et al., Proteins of the PDI family: unpredicted non-ER locations and functions. J Cell Physiol, 2002. 193(2): p. 154-63. 113. Yoshida, H., ER stress and diseases. FEBS J, 2007. 274(3): p. 630-58. 114. Papa, F.R., Endoplasmic reticulum stress, pancreatic beta-cell degeneration, and diabetes. Cold Spring Harb Perspect Med, 2012. 2(9): p. a007666. 115. Lan, H., et al., Distinguishing covariation from causation in diabetes: a lesson from the protein disulfide isomerase mRNA abundance trait. Diabetes, 2004. 53(1): p. 240-4. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/21904 | - |
dc.description.abstract | 第二型糖尿病(Type 2 diabetes)為不可逆之慢性代謝疾病,占總糖尿病人口之90%。根據國際糖尿病聯盟統計,全世界至2015年有將近四億人口受到影響。其成因主要來自胰島素抗性(insulin resistance)增加,影響體內葡萄糖、脂質與蛋白質代謝,進而增加體內氧化壓力最終使胰臟細胞衰竭(β-cell failure)與失能。目前治療糖尿病的諸多方式均無法有效保護而遏止胰島細胞的死亡,進而造成不可逆的傷害而使得糖尿病成為無法治癒之疾病。
實驗室先前研究發現,CPR-1基因為蛋白質雙硫異構酶家族成員之一,主要表現於胰臟與胰島細胞,且CPR-1基因剔除在第二型糖尿病模式鼠 ( CPR-1-/- Leprdb/db ) 可保護胰島細胞功能、降低血糖、減少體內活性氧化物含量、增加血液胰島素濃度進而改善糖尿病。甚至使58%的小鼠血糖完全控制在正常不發病的範圍內;而在本篇研究也發現,若給予高脂飼料與極低劑量之常見胰島專一性毒化物STZ處理可誘發CPR-1基因過度表現B6小鼠 ( CPR-1 tg / B6) 產生糖尿病,但同樣處方式卻不會影響控制組血糖表現,證實CPR-1基因確實為第二型糖尿病之重要指標。在另一方面,先前研究同時發現在42%無法有效控制血糖而形成邊緣型糖尿病(borderline diabetes)之CPR-1基因剔除糖尿病鼠中,小鼠血糖趨勢與攝食量及體重具高度相關。於是本篇研究中利用這42%發病小鼠處理熱量限制(CR)、運動訓練(Ex)與Metformin(Met)複合治療,藉由同時保護β細胞與增加週邊組織對胰島素敏感性達到改善糖尿病的效果。實驗結果顯示,持續的CR與階段性Ex和Met處理,可透過活化週邊組織AMPK路徑改善葡萄糖使用效率,降低胰島素抗性,並同時影響胰臟之胰島素分泌,最終翻轉第二型糖尿病。 在機制實驗中發現,CPR-1基因剔除與野生型糖尿病鼠週邊及胰臟磷酸化AMPK的活化表現相反,因此推論CPR-1的有無可能影響AMPK的活化,且證實兩者間存在交互作用。此篇研究結果也提供了新的方向與可行性在未來治療第二型糖尿病的應用上。 | zh_TW |
dc.description.abstract | Type 2 diabetes (T2D) affects 400 million people in the world, and causes 1.5 million deaths annually. T2D is characterized by a failure of functional β-cells to adapt insulin secretion to compensate for increasing insulin resistance, driving diabetes development. Thus, pancreatic β-cell failure is central to diabetes development. Accumulating data suggest that preserving a portion of functional β-cells can change clinical outcome of diabetes. However, none of current anti-diabetic drugs is clinically effective for this preservation. Therefore, identification of the key players in β-cell dysfunction and death helps understand β-cell pathogenesis and diabetes development and invent new strategies for diabetes treatment.
CPR-1, one of the protein disulfide isomerases (PDI), is primarily expressed in pancreata and islets. Our unpublished data showed that 58% of diabetic mice were diabetes-free in CPR-1-/-db/db mice. In this thesis, I found that the treatment with B6 mice with high fat diet (HFD) and STZ induced T2D in B6 mice expressing CPR-1 transgene. In contrast, the same treatment failed to induce T2D in wild-type B6 littermates. In sharp contrast, 42% of CPR-1-/-db/db mice apparently developed borderline T2D. This dichotomy seemed to be relevant to food intake and body weight. This observation prompted me to investigate the effect of calorie restriction, exercise and metformin treatment in CPR-1-/-db/db mice with diabetic onset. These treatments reversed T2D of the CPR-1-/-db/db mice with diabetic onset. AMP-activated protein kinase (AMPK) is a key enzyme of energy metabolism. Generally, activated AMPK stimulates catabolic pathways (glycolysis, fatty acid oxidation and mitochondrial biogenesis) and inhibits anabolic pathways (gluconeogenesis, glycogen, fatty acid and protein synthesis). In this thesis, mechanistic studies demonstrated that the combination therapy increased insulin sensitivity in peripheral tissues and co-regulated insulin secretion in pancreas via AMPK pathway. Furthermore, the results showed that there are some protein-protein interactions between CPR-1 and AMPK, and CPR-1 could be involved in AMPK activity. In conclusion, a combination of CPR1 deletion with metformin treatment, calorie restriction and exercise can reverse T2D through AMPK pathway, making CPR-1 a novel target of T2D therapy. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T03:52:22Z (GMT). No. of bitstreams: 1 ntu-107-R04642005-1.pdf: 2172783 bytes, checksum: 0fac3c6aa4b5533792a083c28b975206 (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 中文摘要……………………………………………………………………………I
英文摘要 ……………………………………………………………………………III 目錄 …………………………………………………………………………………VII 圖目錄 ………………………………………………………………………………IX 第一章 、前言 ………………………………………………………………………1 第一節 、糖尿病 …………………………………………………………………….1 第二節 、生活型態與第二型糖尿病 …………………..………………….………10 第二節 、單磷酸腺苷活化蛋白質激酶………………………..………………….12 第四節 、蛋白質雙硫異構酶 ……………………………………………………...14 第二章 、材料與方法 ……………………………………………..…………………….16 第一節 、理化實驗器具、藥品與方法 …………………………………………….16 第二節 、實驗動物及其實方法…………………………………………………...21 第三節 、以高脂飼料搭配毒化物 STZ誘發 CPR-1基因轉殖之 C57BL/6糖尿病模式小鼠 ……………………………………………………………………….23 第四節 、熱量限制 (Calorie Restriction, CR)複合治療全身性 CPR-1基因剔除糖尿病鼠 ……………………………………………………………………….23 第五節 、配合運動 (Exercise, Ex)複合治療全身性CPR-1基因剔除糖尿病鼠………………………………………………………………………………… 24 第六節 、給予 metformin複合治療全身性 CPR-1基因剔除糖尿病鼠 ……… 24 第七節 、統計分析 ……………………………………………………...................24 第三章、結果 …………………………………………………………………………...26 第一節、胰臟 CPR-1基因轉殖之B6鼠(CPR-1tg/B6)可透過STZ/HFD誘導產生第二型糖尿病 ………………………………………………………..26 第二節、全身性CPR-1基因剔除搭配熱量限制(Calorie restriction, CR、運動(Exercise, Ex)及Metformin(Met)複合治療可回復第二型糖尿病……………………………………………………………………………….28 第三節、複合治療透過調控週邊組織與胰臟之AMPK活性而改善胰島素抗性與分泌………………………………………………………………………….....32 第四章、討論…………………………………………………………………………33 第一節、CPR-1基因在第二型糖尿病中為影響細胞功能之關鍵角色……….33 第二節、CR、Ex、Met配合CPR-1基因剔除進行複合治療可翻轉第二型糖尿病……………………………………………………………………………….33 第三節、複合治療翻轉糖尿病之機制為調控AMPK活化路徑…………….34 第四節、CPR-1與AMPK之間具有交互作用……………..………………….35 第五章、結論…………………………………………………………………………...36 附圖…………………………………………………………………………………….54 參考文獻……………………………………………………………………………….60 | |
dc.language.iso | zh-TW | |
dc.title | 探討CPR-1基因在第二型糖尿病之治療與應用 | zh_TW |
dc.title | Function and application of CPR-1 gene in type 2 diabetes | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林炎壽,宋麗英,林劭品 | |
dc.subject.keyword | 第二型糖尿病,胰島素抗性,胰島細胞功能,限食,運動,Metformin,AMPK, | zh_TW |
dc.subject.keyword | T2D,Insulin resistance,beta-cell function,Calorie restriction,Exercise,Metformin,AMPK pathway, | en |
dc.relation.page | 67 | |
dc.identifier.doi | 10.6342/NTU201803934 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2018-08-18 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 生物科技研究所 | zh_TW |
顯示於系所單位: | 生物科技研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 2.12 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。